CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 459 enrolled
Drug / intervention
BLI400 Laxative +1 moredrug
Likely dose
Lubiprostone 24 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02481947
NCT02481947Phase 3Completed
CompareCT.gov

A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults

Braintree Laboratories·interventional·Posted Jun 25, 2015·Updated Jul 27, 2020

In Brief

A Phase 3 clinical trial evaluating BLI400 Laxative and Lubiprostone for Chronic Idiopathic Constipation. Completed, enrolled 459 participants across 50 sites.

Detailed Summary

The purpose of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus lubiprostone in constipated adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Idiopathic Constipation
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 25, 2015
Enrollment StartMay 1, 2015
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.0 years ago

Interventions

BLI400 Laxativedrug

21 gm BLI400 powder

Lubiprostonedrug

24 mcg capsule bid